Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2/3 study of oral RPC1063 in relapsing multiple sclerosis
2012-002714-40Phase 2Completed
- Sponsor
- Receptos
- Start
- Mar 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ozanimod in multiple sclerosis (MS) (6 arms), sponsored by Receptos. Primary endpoint: Primary efficacy endpoint. Started Mar 2013; status: completed.
02
Drugs
ozanimod
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2012-002714-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002714-40.